Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293460 | 0.93 | LMNA (0.35) | LMNAALDH1A1TSHRALOX12MAPK1 | |
| SCHEMBL16296562 | 0.92 | — | — | |
| SCHEMBL16296623 | 0.90 | MTNR1B (0.37) | — | |
| SCHEMBL17705282 | 0.87 | LMNA (0.38) | LMNAALDH1A1TSHRALOX12MAPK1 | |
| SCHEMBL18892538 | 0.84 | LMNA (0.36) | LMNAALDH1A1TSHRALOX12MAPK1 | |
| SCHEMBL17700694 | 0.81 | PTGES (0.34) | LMNAALDH1A1MAPK1HSD17B10MEN1 | |
| SCHEMBL17705278 | 0.79 | LMNA (0.41) | LMNAALDH1A1TSHRALOX12MAPK1 | |
| SCHEMBL18892424 | 0.77 | LMNA (0.39) | LMNAALDH1A1TSHRALOX12MAPK1 | |
| SCHEMBL16293856 | 0.76 | POLB (0.37) | LMNAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL17700672 | 0.73 | GSTO1 (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | LMNA 963/4885ALDH1A1 2603/4885TSHR 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.